Terry Dunlay and Lansing Taylor have been awarded US Patent No. 6,902,883, "System for cell-based screening."
Dunlay and Taylor are the inventors. Dunlay is the vice-president of informatics at Cellomics. Taylor is a founder and former chairman of Cellomics, and current CEO of Cellumen.
According to its abstract, the patent protects an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment, or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96-well or 384-well microtiter plate, or a microplate having cells in a micropatterned array of locations. The invention includes apparatus and computerized method[s] for processing, displaying, and storing the data, the abstract states.
Apoptosis Technology has been awarded US Patent No. 6,902,885, "Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products."
Inventors listed on the patent are Viktor Goldmakher, Anna Skaletskaya, and Laura Bartle.
According to its abstract, the patent protects novel polypeptides having anti-apoptotic activity, methods of screening for such polypeptides, and polynucleotides encoding such polypeptides. The patent also protects compounds that regulate or modulate apoptosis and/or anti-apoptotic activity (such as compounds having anti-apoptotic activity, and such as compounds that induce, restore, or modulate apoptosis and/or inhibit, diminish, or modulate anti-apoptotic activity); methods of screening for such compounds; and methods of using such compounds in the therapeutic treatment of diseases, the abstract states. The patent also protects methods of treating eukaryotic cells with compounds that regulate or modulate apoptosis and/or anti-apoptotic activity; methods of enhancing the stability, growth, and/or productivity of eukaryotic cells; and pharmaceutical compositions that regulate or modulate apoptosis and/or anti-apoptotic activity, the abstract states.
LJL Biosystems has been awarded US Patent No. 6,902,703, "Integrated sample-processing system."
Inventors listed on the patent are Samuel Marquiss, Christopher Cesar, Jon Peterson, David Stumbo, Amer El-Hage, Glenn Edwards, Douglas Modlin, Lev Leytes, and Samuel Burd.
According to its abstract, the patent protects an integrated sample-processing system and components thereof for preparing and/or analyzing samples. The components may include a transport module, a fluidics module, and an analysis module, among others, the abstract states